Q32 Bio (QTTB) Operating Margin (2018 - 2023)
Q32 Bio (QTTB) recorded quarterly Operating Margin of 1897.72% in Q4 2023, up 552.41% quarter-over-quarter from 419.47% in Q3 2023, and down 1030752.0% on a YoY basis from N/an in Q4 2022.
Q32 Bio (QTTB) Operating Margin (2018 - 2023) Analysis & Trends
Q32 Bio's Operating Margin history runs 6 years deep, the most recent figure standing at 1897.72% for Q4 2023.
- In Q4 2023, Operating Margin fell 1030752.0% year-over-year to 1897.72%; the TTM figure through Sep 2024 stood at 5690.07% (up 483407.0% YoY), while the FY2025 annual figure was 31.45%, changed N/A from the prior year.
- Operating Margin was 1897.72% for Q4 2023 at Q32 Bio, up from 419.47% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 12205.24% in Q4 2022 to a low of 9304.81% in Q1 2019.
- Historically, Operating Margin has averaged 2284.08% across 5 years, with a median of 3285.29% in 2022.
- The sharpest annual moves came in 2021 and 2023: Operating Margin surged 830449 bps in 2021, then slumped 1030752 bps in 2023.
- A 5-year view of Operating Margin shows it stood at 4539.79% in 2019, then soared by 33 bps to 3041.02% in 2020, then surged by 273 bps to 5263.47% in 2021, then surged by 132 bps to 12205.24% in 2022, then plunged by 84 bps to 1897.72% in 2023.
- The last three Operating Margin figures came in at 1897.72% (Q4 2023), 419.47% (Q3 2023), and 226.99% (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Q32 Bio | 167.59 Mn | 116.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1,897.72% |
| Sep 30, 2023 | -419.47% |
| Jun 30, 2023 | -226.99% |
| Mar 31, 2023 | -250.19% |
| Dec 31, 2022 | 12,205.24% |
| Sep 30, 2022 | -4,097.51% |
| Jun 30, 2022 | -3,529.55% |
| Mar 31, 2022 | -4,690.52% |
| Dec 31, 2021 | 5,263.47% |
| Sep 30, 2021 | -1,828.32% |
| Jun 30, 2021 | -1,396.98% |
| Mar 31, 2021 | -3.79% |
| Dec 31, 2020 | -3,041.02% |
| Sep 30, 2020 | -4,986.42% |
| Jun 30, 2020 | -6,295.77% |
| Mar 31, 2020 | -6,206.12% |
| Dec 31, 2019 | -4,539.79% |
| Sep 30, 2019 | -7,094.78% |
| Jun 30, 2019 | -7,135.97% |
| Mar 31, 2019 | -9,304.81% |